You are here

Clinical Department of Nuclear Medicine

Nuclear medicine is a branch of medicine that uses active isotopes (radionuclides) to diagnose and treat diseases. Radionuclides are atoms with unstable core that reduce their energy by emitting ionising radiation. In the field of nuclear medicine, active isotopes are combined with specific chemical complexes to create radio-pharmaceutical substances (RPS). After being injected into patient’s organism, these substances are absorbed by specific tissues or organs.

The work carried out by the Clinical Department of Nuclear Medicine may be functionally divided in 2 categories:

  • diagnostic nuclear medicine – scintigraphy services for patients of the Riga East Clinical University Hospital;
  • therapeutic nuclear medicine – treatment in the in-patient department by using active isotopes, as well as out-patient admission of new and recurrent patients.

The Clinical Department of Nuclear Medicine has the following:

  • one in-patient department (on the 1st floor of the In-patient Department “Latvian Oncology Centre”);
  • department of out-patient admission (on the 1st floor of the In-patient Department “Latvian Oncology Centre”, rooms from 130 through 139);
  • two diagnostic scintigraphy devices which  ensure a possibility of performing SPECT/CT examination (Infinia Hawkeye) or just SPECT examination (SKY Light) in addition to the planar scintigraphy.

Therapeutic nuclear medicine (treatment)

The Clinical Department of Nuclear Medicine is the only in-patient department of therapeutic nuclear medicine in Latvia, which carries out treatment by using high-activity radio-pharmaceutical substances.

Iodine–131 therapy:

  • for patients with follicular or papillary thyroid cancer;
  • for patients with benign thyroid diseases.

Iodine 131 mIBG therapy:

for patients with medullary thyroid cancer, neuroblastama, and other neuro-endocrine tumours.

The department has 15 in-patient beds with specialized, isolated single rooms and radiation-safe infrastructure, continuous dosimetry control, and restriction of visits. In case of therapeutic nuclear medicine, after the injection of radio-pharmaceutical substances patients are isolated in separate rooms until the activity of substances in patient’s body decreases to the level allowed by regulatory enactments.

Diagnostic nuclear medicine (scintigraphy)

Specialists of this field assess the functional condition of organs or systems of organs by using radio-pharmaceutical substances with relatively low radioactivity solely for the purposes of diagnostic visualisation. Often enough, nuclear medicine can diagnose diseases earlier than other methods of visual diagnostics, when there are functional changes only and no damages of the structure of organs.

The following examinations may be carried out in the Clinical Department of Nuclear Medicine:

  • scintigraphy of the thyroid;
  • scintigraphy of kidneys;
  • scintigraphy of epithelial bodies;
  • diagnostic scintigraphy of the sentinel lymph node;
  • scintigraphy of the body by using different radio-pharmaceutical substances for oncology patients;
  • scintigraphy of the skeleton;
  • myocardial perfusion scintigraphy;
  • additional SPECT/CT examination for specifying the antomic-topographic localisation of the locus for patients who undergo scintigraphy of the body, skeleton, or sentinel lymph node;
  • radiometry to calculate the dose of I-131 therapy.

At the reception desk, when registering for scintigraphy examination, you will receive all necessary information on medicinal products that cannot be used prior to the examination (e.g., iodine and iodine-containing products prior to the scintigraphy of the thyroid); it is to be taken into account that the scintigraphy examination of the skeleton requires 3-4 hours; therefore, after radio-pharmaceutical substances have been injected, patients have to stay in special waiting premises and use the toilet intended for them only.

Out-patient work:

The radiologists/therapists of the Clinical Department of Nuclear Medicine carry out primary out-patient admission of patients with thyroid cancer and further observation of patients after the received therapy, as well as consult patients with benign thyroid diseases, assessing the indications for I-131 therapy, and carrying out further therapy and control of patients at the out-patient stage after the received I-131 therapy.

131-I therapy for patients suffering from thyroid cancer


        1700,- EUR


  • 6 bed days in hospital (single room with shower, WC, refrigerator, TV set, hair dryer, and WIFI);
  • necessary tests before 131-I therapy;
  • ultrasound of thyroid gland and cervical lymph nodes;
  • electrocardiogramme;
  • body scintigraphy using SPECT/CT after the therapy.


     Antra Bērziņa, head of the Clinical Department of Nuclear Medicine of the Clinic of Therapeutic Radiology and Medical Physics:

        Telephone  +371 67042248


    Ginta Lāce, senior radiologist's assistant:

  Telephone +371 67042059


     Additional service:

  • We can provide invitations for visa, if required


Head of the Department Dr. Antra Bērziņa

Senior Hospital Physician Dr. Daina Bērziņa

Radiologist/therapist Dr. Lilita Roznere

Radiologist/diagnostician Dr. Genādijs Storoženko

Last update: 2015.02.27 - 10:37